<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27033" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Permethrin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nanda</surname>
            <given-names>Japbani</given-names>
          </name>
          <aff>Renaissance School of Medicine at Stony Brook University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Juergens </surname>
            <given-names>Andrew L.</given-names>
          </name>
          <aff>Texas A&#x00026;M</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Japbani Nanda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrew Juergens declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27033.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Permethrin, a synthetic pyrethroid categorized as a synthetic neurotoxic pyrethroid, is approved for treating scabies and pediculosis capitis. This medication operates within the arthropod nervous system, specifically targeting eggs, lice, and mites. Permethrin exerts its therapeutic effect by disrupting sodium transport across neuronal membranes in arthropods, inducing depolarization. This mechanism ultimately leads to respiratory paralysis in the affected arthropod, establishing permethrin as a potent agent in managing scabies and pediculosis. This activity will comprehensively cover permethrin's indications, mode of action, and contraindications, equipping healthcare team members with essential knowledge to treat patients with scabies and pediculosis effectively.</p>
        <p>This discussion&#x000a0;includes primary indications and action and permethrin's adverse event profile, monitoring requirements, warnings, and potential toxicity. Healthcare professionals engaging in this activity gain an understanding of the considerations crucial for the safe and effective administration of permethrin in the context of scabies and pediculosis treatment. The&#x000a0;course provides healthcare team members with the necessary insights to navigate the complexities associated with permethrin therapy, ensuring optimal patient care and outcomes in the targeted conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate indications for permethrin therapy in treating scabies and pediculosis.</p></list-item><list-item><p>Assess the response to permethrin treatment and evaluate the resolution of scabies or pediculosis symptoms.</p></list-item><list-item><p>Select the appropriate formulation and concentration of permethrin based on patient characteristics, severity of infestation, and treatment goals.</p></list-item><list-item><p>Develop communication&#x000a0;with patients about the benefits, potential adverse effects, and proper use of permethrin, ensuring their understanding and compliance.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27033&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27033">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27033.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The United States Food and Drug Administration (FDA) has approved using permethrin, a synthetic pyrethroid, to treat scabies and pediculosis capitis.<xref ref-type="bibr" rid="article-27033.r1">[1]</xref>&#x000a0;</p>
        <p>A patient with classic scabies often presents with generalized pruritus that is exacerbated overnight with inflammatory papules primarily localized to the area between the fingers, flexural sites, genitalia, breasts, and buttocks with or without burrows (see <bold>Images.&#x000a0;</bold>Rash and Scabies sites, Scabies Burrows, Scabies Scaly Patch).&#x000a0;The clinical diagnosis of pediculosis capitis relies upon the detection of living lice (see <bold>Images.&#x000a0;</bold>Crusted Scabies, Scabies in Skin Scraping.).<xref ref-type="bibr" rid="article-27033.r2">[2]</xref>&#x000a0;</p>
        <p>Several studies have assessed the effectiveness and safety of permethrin compared with other scabies treatments. A review of clinical trials showed low-certainty evidence demonstrating that after&#x000a0;2 weeks of administration, 5% permethrin cream and 200 &#x003bc;g/kg of oral ivermectin demonstrated similar efficacy for treating scabies. However, clearance may be inferior after the first week when using oral ivermectin. There was moderate certainty evidence to conclude that the proportion of patients with&#x000a0;1 or more drug-related adverse events was similar to those treated with permethrin cream or oral ivermectin.<xref ref-type="bibr" rid="article-27033.r3">[3]</xref>&#x000a0;</p>
        <p>A recent network meta-analysis evaluating randomized controlled trials found that treatment with combined permethrin and oral ivermectin for scabies was associated with the highest cure rate. However, combination treatment was not significantly better than permethrin alone; only one randomized controlled trial included this combination treatment. This analysis also found that permethrin was less often associated with persistent itching than other studied treatments, like crotamiton and lindane, but was outperformed by topical ivermectin in this category.</p>
        <p>The risk of adverse events was lowest with synergized pyrethrins, but permethrin scored better than several treatments, such as lindane and topical ivermectin. The treatment of choice for a particular patient should be guided by several factors, including efficacy, safety profile, and the ability to administer the medication properly.<xref ref-type="bibr" rid="article-27033.r4">[4]</xref>&#x000a0;</p>
        <p>Per European guidelines, classical scabies can be treated with 5% permethrin cream, 200 &#x003bc;g/kg of oral ivermectin, or 10% to 25% benzyl benzoate lotion.<xref ref-type="bibr" rid="article-27033.r5">[5]</xref>&#x000a0;In the United States, 5% topical permethrin cream is a first-line treatment option for scabies. Patients may benefit from combined treatment with a topical medication, such as 5% permethrin cream and 200 &#x003bc;g/kg of oral ivermectin to treat crusted scabies.&#x000a0;However, the best treatment for crusted scabies remains undetermined due to insufficient research.<xref ref-type="bibr" rid="article-27033.r6">[6]</xref>&#x000a0;</p>
        <p>In endemic regions and during a scabies epidemic, the large&#x000a0;patient population&#x000a0;can more easily receive treatment with 200 &#x003bc;g/kg of oral ivermectin than with topical medications.<xref ref-type="bibr" rid="article-27033.r5">[5]</xref>&#x000a0;Also, clinicians should treat close contacts and sexual partners&#x000a0;from the prior&#x000a0;2 months.<xref ref-type="bibr" rid="article-27033.r7">[7]</xref>&#x000a0;Maintaining personal hygiene and washing items, such as clothes and bedsheets, at high temperatures is essential. Items can also be sealed within a bag for at least&#x000a0;2 to&#x000a0;3 days as an alternative. Some patients may continue to experience pruritus for&#x000a0;4 weeks after proper treatment.<xref ref-type="bibr" rid="article-27033.r8">[8]</xref></p>
        <p>A common first-line treatment option for pediculosis capitis is 1% permethrin lotion, which is available over the counter in many countries.<xref ref-type="bibr" rid="article-27033.r9">[9]</xref>&#x000a0;A systematic review of trials that evaluated medications for the treatment of pediculosis capitis suggested that permethrin was efficacious.<xref ref-type="bibr" rid="article-27033.r10">[10]</xref>&#x000a0;However, permethrin has been associated with widespread resistance, and newer options that physically target lice, such as dimethicone, have been studied.<xref ref-type="bibr" rid="article-27033.r11">[11]</xref><xref ref-type="bibr" rid="article-27033.r12">[12]</xref>&#x000a0;</p>
        <p>A recent trial found that treatment of pediculosis capitis with dimethicone was associated with significantly higher cure rates than treatment with 1% permethrin lotion.<xref ref-type="bibr" rid="article-27033.r13">[13]</xref>&#x000a0;The best treatment option for a particular patient must consider local resistance.<xref ref-type="bibr" rid="article-27033.r2">[2]</xref>&#x000a0;</p>
        <p>When treating&#x000a0;pediculosis, pediculicide product labels only address their use to treat pediculosis capitis. Treatment of pediculosis corporis relies upon good personal hygiene and appropriate washing of clothes, but a topical pediculicide could also aid in treatment.<xref ref-type="bibr" rid="article-27033.r14">[14]</xref>&#x000a0;A 1% permethrin cream has been recommended to treat pediculosis pubis as part of a broader regimen that includes cleansing of clothes and linens, sexual abstinence during treatment, and treatment of sexual partners from the prior month.<xref ref-type="bibr" rid="article-27033.r6">[6]</xref>&#x000a0;Meanwhile, European guidelines recommend the treatment of sexual partners from the preceding&#x000a0;3 months.<xref ref-type="bibr" rid="article-27033.r7">[7]</xref></p>
      </sec>
      <sec id="article-27033.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Permethrin is a neurotoxic synthetic pyrethroid.&#x000a0;The drug targets eggs, lice, and mites.<xref ref-type="bibr" rid="article-27033.r15">[15]</xref>&#x000a0;Permethrin affects sodium transport across neuronal membranes in arthropods, thus causing depolarization.&#x000a0;The result is respiratory paralysis of the affected arthropod.<xref ref-type="bibr" rid="article-27033.r14">[14]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Topical permethrin is associated with limited dermal or systemic absorption.<xref ref-type="bibr" rid="article-27033.r16">[16]</xref>&#x000a0;Less than&#x000a0;2%&#x000a0;of applied permethrin is absorbed through human skin.<xref ref-type="bibr" rid="article-27033.r1">[1]</xref></p>
        <p><bold>Distribution:</bold> Pharmacokinetic distribution property has not been&#x000a0;examined despite its widespread use. A study was conducted in 2019 to assess the plasma protein and lipoprotein Binding of cis- and trans-permethrin and deltamethrin in adult humans and rats. The study revealed that pyrethroid has high plasma protein binding (90%), and lipoprotein plays a significant role in&#x000a0;binding and transport.<xref ref-type="bibr" rid="article-27033.r17">[17]</xref></p>
        <p><bold>Metabolism:</bold> Permethrin quickly undergoes esterase hydrolysis and detoxification within the body.<xref ref-type="bibr" rid="article-27033.r1">[1]</xref>&#x000a0;The liver carries many of the carboxylesterases that hydrolyze permethrin.<xref ref-type="bibr" rid="article-27033.r18">[18]</xref>&#x000a0;The liver also has cytochrome P450 enzymes that oxidize permethrin into metabolites.<xref ref-type="bibr" rid="article-27033.r19">[19]</xref></p>
        <p><bold>Excretion:</bold> During the 72 hours after topical application, permethrin's inactive metabolites undergo nearly complete excretion into the urine.<xref ref-type="bibr" rid="article-27033.r1">[1]</xref>&#x000a0;Permethrin's postulated lethal oral dose is 1 to 2 g/kg of body weight in humans.<xref ref-type="bibr" rid="article-27033.r16">[16]</xref></p>
      </sec>
      <sec id="article-27033.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Permethrin is available as a cream (5%), permethrin lotion (1%), and permethrin rinse (1%).</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p><bold>Classical Scabies</bold>: 5%&#x000a0;permethrin cream&#x000a0;can be applied topically to cool, dry skin from the patient's head to their toes and under the fingernails.<xref ref-type="bibr" rid="article-27033.r5">[5]</xref>&#x000a0;The cream is washed off after 8 to 14 hours and is often reapplied the same way&#x000a0;1 week later.<xref ref-type="bibr" rid="article-27033.r8">[8]</xref>&#x000a0;</p>
        <p>Per European guidelines for crusted scabies, 5% permethrin cream can be applied topically every day for&#x000a0;1 week, followed by application twice a week until resolution, along with 200 &#x003bc;g/kg of oral ivermectin administered at a specified dosing interval over several days.<xref ref-type="bibr" rid="article-27033.r5">[5]</xref>&#x000a0;Patients should avoid contact with mucosal sites when applying topical permethrin.<xref ref-type="bibr" rid="article-27033.r8">[8]</xref><bold>&#x000a0;</bold></p>
        <p>Scabies rarely infests the scalp of adults, but the hairline, neck, temples, and forehead may be infested in infants and geriatric patients; therefore, the clinician should instruct the caregiver to apply 5% cream to the entire head and neck, including the scalp, temples, and forehead.</p>
        <p><bold>Pediculosis Capitis</bold>: Apply 1% permethrin to dampened hair and wash off after&#x000a0;10 minutes with a repeat application&#x000a0;1 week later.<xref ref-type="bibr" rid="article-27033.r20">[20]</xref>&#x000a0;However, other reapplication timeframes have been proposed, such as reapplication 7 and 13 to 15 days after initial treatment.<xref ref-type="bibr" rid="article-27033.r21">[21]</xref>&#x000a0;To treat pediculosis pubis, 1% topical permethrin cream is rinsed off 10 minutes after application.<xref ref-type="bibr" rid="article-27033.r6">[6]</xref>&#x000a0;Avoid contact with eyes as there is a possibility of ocular irritation. Hence, clinicians should not use it to treat pediculosis of the eyebrows and eyelashes. If accidental contact with the eyes occurs, the person should wash the affected eye(s) thoroughly with water.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> The manufacturer's labeling provides no information regarding the use in patients with hepatic impairment.</p>
        <p><bold>Renal impairment:</bold> The manufacturer's labeling provides no information regarding the use in&#x000a0;patients with&#x000a0;renal impairment. However, permethrin is primarily metabolized by the liver, so hypothetically, it should be safe for patients with renal impairment.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Permethrin has not been shown to cause human risk and has been in the former FDA pregnancy category B.<xref ref-type="bibr" rid="article-27033.r8">[8]</xref>&#x000a0;Permethrin is the preferred medication for pediculosis pubis and scabies during pregnancy.<xref ref-type="bibr" rid="article-27033.r6">[6]</xref>&#x000a0;</p>
        <p><bold>Breastfeeding considerations:</bold> Topical permethrin is acceptable in nursing mothers as less than 2% is absorbed after topical application, and permethrin is rapidly metabolized. Extensive exposure, such as agricultural use or malaria control, might have long-term health concerns because residues can be found in breast milk. Clinicians should instruct the patient to use only water-miscible cream, gel, or liquid products on the breast because ointments may expose the infant to increased concentrations of mineral paraffin via licking.&#x000a0;In addition, breastmilk samples from 79 women from a study at the University of California Davis had their breastmilk examined for trans-permethrin on day 42 postpartum; the mean concentration was in the acceptable range.<xref ref-type="bibr" rid="article-27033.r22">[22]</xref></p>
      </sec>
      <sec id="article-27033.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects reported during the treatment of scabies with permethrin include increased or new onset of pruritus, burning, or a stinging sensation.&#x000a0;These dermatologic adverse events were mild in severity and temporary.<xref ref-type="bibr" rid="article-27033.r23">[23]</xref>&#x000a0;There have also been reports of stinging when applying 1% permethrin for pediculosis capitis.<xref ref-type="bibr" rid="article-27033.r24">[24]</xref>&#x000a0;</p>
        <p>When used for pediculosis capitis, the rash has been reported as an adverse drug reaction.<xref ref-type="bibr" rid="article-27033.r25">[25]</xref>&#x000a0;Localized temporary paresthesia, cutaneous irritation, and allergic contact dermatitis are also possible, yet rare, adverse effects associated with permethrin use.<xref ref-type="bibr" rid="article-27033.r26">[26]</xref>&#x000a0;A rare case report exists of a patient presenting with muscle dystonia attributed to&#x000a0;5% topical permethrin.<xref ref-type="bibr" rid="article-27033.r27">[27]</xref></p>
      </sec>
      <sec id="article-27033.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The FDA has not approved permethrin for use in infants&#x000a0;younger than 2 months, and limited studies have taken place to assess the use of this medication in these patients.<xref ref-type="bibr" rid="article-27033.r28">[28]</xref>&#x000a0;However, recent research suggests that 5% permethrin cream can safely treat scabies in this infant population.<xref ref-type="bibr" rid="article-27033.r29">[29]</xref>&#x000a0;Also, care is necessary to avoid inappropriate administration because some patients may be allergic to the medication&#x02019;s formulation.<xref ref-type="bibr" rid="article-27033.r30">[30]</xref>&#x000a0;Permethrin cream is contraindicated in persons with known hypersensitivity to any of its components, pyrethroid or pyrethrin.</p>
      </sec>
      <sec id="article-27033.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p><bold>Scabies:</bold> As per European guidelines, patients with scabies should return for a follow-up&#x000a0;2 weeks after treatment has ended to assess for resolution.<xref ref-type="bibr" rid="article-27033.r5">[5]</xref>&#x000a0;</p>
        <p><bold>Pediculosis:</bold> If symptoms of pediculosis pubis remain, patients should return for a follow-up&#x000a0;1 week later to assess for remaining lice or eggs.<xref ref-type="bibr" rid="article-27033.r6">[6]</xref></p>
      </sec>
      <sec id="article-27033.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p><bold>Carcinogenesis, mutagenesis, and impairment of fertility:</bold>&#x000a0;6 carcinogenicity bioassays were evaluated with permethrin. No tumorigenicity has been observed in the rat studies. However, the&#x000a0;3 mouse studies saw an increase in pulmonary adenomas. In one of these studies, there was a raised incidence of pulmonary alveolar-cell carcinomas and benign liver adenomas in female mice. Permethrin exhibited no mutagenic potential in&#x000a0;genetic toxicity studies (in vitro and in vivo). Permethrin did not adversely impact reproductive function when given orally at a 180 mg/kg/d dose in a 3-generation rat study.</p>
        <p>In humans, permethrin's postulated lethal oral dose is 1 to 2 g/kg of human body weight.<xref ref-type="bibr" rid="article-27033.r16">[16]</xref>&#x000a0;Although reports of toxicity exist when using permethrin as an insecticide, there are only a few adverse events associated with its topical use.<xref ref-type="bibr" rid="article-27033.r27">[27]</xref>&#x000a0;</p>
        <p>Signs of toxicity and metabolic acidosis were reported following the excessive application of 5% topical permethrin when treating a 20-month-old patient with scabies.<xref ref-type="bibr" rid="article-27033.r31">[31]</xref>&#x000a0;Also,&#x000a0;2 siblings exposed to permethrin, a type I pyrethroid pesticide, experienced neurotoxic effects. Clinicians pursued supportive treatment because there is no antidote for permethrin toxicity.<xref ref-type="bibr" rid="article-27033.r32">[32]</xref></p>
      </sec>
      <sec id="article-27033.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The coordination of an interprofessional team of healthcare providers is critical to ensure optimal healthcare outcomes for patients who receive therapy with topical permethrin for scabies or pediculosis. Patients with scabies or pediculosis may present to healthcare&#x000a0;providers in various fields, such as primary care, urgent care, emergency medicine, pediatrics, family medicine, internal medicine, or dermatology. School nurses and health professionals may identify a child with pediculosis capitis and facilitate communication with the child's caregivers to start timely treatment.<xref ref-type="bibr" rid="article-27033.r9">[9]</xref></p>
        <p>Treatment outcomes and safety depend on the proper use of topical permethrin.<xref ref-type="bibr" rid="article-27033.r8">[8]</xref>&#x000a0;Therefore, patients and caregivers should receive written instructions for applying topical permethrin in addition to verbal explanations. Such instructions are also essential to avoid accidental misuse or overuse of the medication. Clinicians,&#x000a0;including infectious disease specialists, can help patients and caregivers understand medication administration instructions and monitor adequate treatment response. Pharmacists may also clarify these instructions if questions arise, verify dosing, and&#x000a0;verify no drug interactions exist in the patient's medication profile.</p>
        <p>Other treatment options should be&#x000a0;considered in areas with local resistance to permethrin.<xref ref-type="bibr" rid="article-27033.r2">[2]</xref>&#x000a0;Pharmacists can work with physicians and other health professionals to find an appropriate medication for each patient. Also, patients with pediculosis pubis should be assessed for other sexually transmitted infections and may need a referral to an appropriate specialist.<xref ref-type="bibr" rid="article-27033.r6">[6]</xref>&#x000a0;There must be coordinated care between many healthcare team members because close contacts and sexual partners of patients with scabies and pediculosis pubis should have treatment to prevent re-infestation.<xref ref-type="bibr" rid="article-27033.r7">[7]</xref>&#x000a0;Coordinating health care efforts with open communication channels allows patients to&#x000a0;benefit from the&#x000a0;care of&#x000a0;an organized interprofessional team of health professionals.</p>
      </sec>
      <sec id="article-27033.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27033&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27033">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27033/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27033">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-27033.s11">
        <fig id="article-27033.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Crusted Scabies <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="crusted__scabies" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27033.s12">
        <fig id="article-27033.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Scabies Burrows <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="scabies__burrows" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27033.s13">
        <fig id="article-27033.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Rash and Scabies Sites Contributed by&#x000a0;CDC, Public Domain.&#x000a0;Mikael H&#x000e4;ggstr&#x000f6;m&#x000a0;</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Sites_of_scabies" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27033.s14">
        <fig id="article-27033.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Scabies Scaly Patch Contributed by Wikimedia Commons, Michael Geary (Public Domain)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Scabies-burrow" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27033.s15">
        <fig id="article-27033.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Scabies in Skin Scraping Contributed by CDC, Public Domain.&#x000a0;https://www.cdc.gov/parasites/scabies/index.html</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Scabies__in__skin__scraping" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-27033.s16">
        <title>References</title>
        <ref id="article-27033.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taplin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Meinking</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>Pyrethrins and pyrethroids in dermatology.</article-title>
            <source>Arch Dermatol</source>
            <year>1990</year>
            <month>Feb</month>
            <volume>126</volume>
            <issue>2</issue>
            <fpage>213</fpage>
            <page-range>213-21</page-range>
            <pub-id pub-id-type="pmid">2405780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dodd</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Treatment of head lice.</article-title>
            <source>BMJ</source>
            <year>2001</year>
            <month>Nov</month>
            <day>10</day>
            <volume>323</volume>
            <issue>7321</issue>
            <fpage>1084</fpage>
            <pub-id pub-id-type="pmid">11701562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosumeck</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nast</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dressler</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Ivermectin and permethrin for treating scabies.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Apr</month>
            <day>02</day>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>CD012994</fpage>
            <pub-id pub-id-type="pmid">29608022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thadanipon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Anothaisintawee</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rattanasiri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thakkinstian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Attia</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of antiscabietic agents: A systematic review and network meta-analysis of randomized controlled trials.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2019</year>
            <month>May</month>
            <volume>80</volume>
            <issue>5</issue>
            <fpage>1435</fpage>
            <page-range>1435-1444</page-range>
            <pub-id pub-id-type="pmid">30654070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salavastru</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Chosidow</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Boffa</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Janier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tiplica</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>European guideline for the management of scabies.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>8</issue>
            <fpage>1248</fpage>
            <page-range>1248-1253</page-range>
            <pub-id pub-id-type="pmid">28639722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Workowski</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Bolan</surname>
                <given-names>GA</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention</collab>
            </person-group>
            <article-title>Sexually transmitted diseases treatment guidelines, 2015.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2015</year>
            <month>Jun</month>
            <day>05</day>
            <volume>64</volume>
            <issue>RR-03</issue>
            <fpage>1</fpage>
            <page-range>1-137</page-range>
            <pub-id pub-id-type="pmid">26042815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiplica</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Radcliffe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gomberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nandwani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rafila</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nedelcu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Salavastru</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>2015 European guidelines for the management of partners of persons with sexually transmitted infections.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>29</volume>
            <issue>7</issue>
            <fpage>1251</fpage>
            <page-range>1251-7</page-range>
            <pub-id pub-id-type="pmid">25951082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chosidow</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Clinical practices. Scabies.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Apr</month>
            <day>20</day>
            <volume>354</volume>
            <issue>16</issue>
            <fpage>1718</fpage>
            <page-range>1718-27</page-range>
            <pub-id pub-id-type="pmid">16625010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devore</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Schutze</surname>
                <given-names>GE</given-names>
              </name>
              <collab>Council on School Health and Committee on Infectious Diseases, American Academy of Pediatrics</collab>
            </person-group>
            <article-title>Head lice.</article-title>
            <source>Pediatrics</source>
            <year>2015</year>
            <month>May</month>
            <volume>135</volume>
            <issue>5</issue>
            <fpage>e1355</fpage>
            <page-range>e1355-65</page-range>
            <pub-id pub-id-type="pmid">25917986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vander Stichele</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Dezeure</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Bogaert</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of clinical efficacy of topical treatments for head lice.</article-title>
            <source>BMJ</source>
            <year>1995</year>
            <month>Sep</month>
            <day>02</day>
            <volume>311</volume>
            <issue>7005</issue>
            <fpage>604</fpage>
            <page-range>604-8</page-range>
            <pub-id pub-id-type="pmid">7545045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feldmeier</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Pediculosis capitis: new insights into epidemiology, diagnosis and treatment.</article-title>
            <source>Eur J Clin Microbiol Infect Dis</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>9</issue>
            <fpage>2105</fpage>
            <page-range>2105-10</page-range>
            <pub-id pub-id-type="pmid">22382818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Soltani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Azizi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Faramarzi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Moemenbellah-Fard</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Comparative efficacy of three pediculicides to treat head lice infestation in primary school girls: a randomised controlled assessor blind trial in rural Iran.</article-title>
            <source>BMC Dermatol</source>
            <year>2019</year>
            <month>Sep</month>
            <day>12</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <pub-id pub-id-type="pmid">31510998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heukelbach</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pilger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Khakban</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ariza</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Feldmeier</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A highly efficacious pediculicide based on dimeticone: randomized observer blinded comparative trial.</article-title>
            <source>BMC Infect Dis</source>
            <year>2008</year>
            <month>Sep</month>
            <day>10</day>
            <volume>8</volume>
            <fpage>115</fpage>
            <pub-id pub-id-type="pmid">18783606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ko</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Elston</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Pediculosis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-12; quiz 13-4</page-range>
            <pub-id pub-id-type="pmid">14699358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tjioe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vissers</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Scabies outbreaks in nursing homes for the elderly: recognition, treatment options and control of reinfestation.</article-title>
            <source>Drugs Aging</source>
            <year>2008</year>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>299</fpage>
            <page-range>299-306</page-range>
            <pub-id pub-id-type="pmid">18361540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomalik-Scharte</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lazar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meins</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bastian</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ihrig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wachall</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jetter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tantcheva-Po&#x000f3;r</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mahrle</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fuhr</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Dermal absorption of permethrin following topical administration.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>61</volume>
            <issue>5-6</issue>
            <fpage>399</fpage>
            <page-range>399-404</page-range>
            <pub-id pub-id-type="pmid">15947923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sethi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bruckner</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Mortuza</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Cummings</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Muralidhara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Plasma Protein and Lipoprotein Binding of <italic>Cis</italic>- and <italic>Trans</italic>-Permethrin and Deltamethrin in Adult Humans and Rats.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>47</volume>
            <issue>9</issue>
            <fpage>941</fpage>
            <page-range>941-948</page-range>
            <pub-id pub-id-type="pmid">31248885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crow</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Borazjani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Potter</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Hydrolysis of pyrethroids by human and rat tissues: examination of intestinal, liver and serum carboxylesterases.</article-title>
            <source>Toxicol Appl Pharmacol</source>
            <year>2007</year>
            <month>May</month>
            <day>15</day>
            <volume>221</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">17442360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Willemin</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kadar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Sousa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Leclerc</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rahmani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brochot</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>In vitro human metabolism of permethrin isomers alone or as a mixture and the formation of the major metabolites in cryopreserved primary hepatocytes.</article-title>
            <source>Toxicol In Vitro</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>803</fpage>
            <page-range>803-12</page-range>
            <pub-id pub-id-type="pmid">25765475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gunning</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kiraly</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pippitt</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Lice and Scabies: Treatment Update.</article-title>
            <source>Am Fam Physician</source>
            <year>2019</year>
            <month>May</month>
            <day>15</day>
            <volume>99</volume>
            <issue>10</issue>
            <fpage>635</fpage>
            <page-range>635-642</page-range>
            <pub-id pub-id-type="pmid">31083883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lebwohl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Levitt</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Therapy for head lice based on life cycle, resistance, and safety considerations.</article-title>
            <source>Pediatrics</source>
            <year>2007</year>
            <month>May</month>
            <volume>119</volume>
            <issue>5</issue>
            <fpage>965</fpage>
            <page-range>965-74</page-range>
            <pub-id pub-id-type="pmid">17473098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <chapter-title>Permethrin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schultz</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Menter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Judson</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Mertz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Handsfield</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Comparative study of 5% permethrin cream and 1% lindane lotion for the treatment of scabies.</article-title>
            <source>Arch Dermatol</source>
            <year>1990</year>
            <month>Feb</month>
            <volume>126</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-70</page-range>
            <pub-id pub-id-type="pmid">1689135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burgess</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Burgess</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Brunton</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Tocopheryl acetate 20% spray for elimination of head louse infestation: a randomised controlled trial comparing with 1% permethrin creme rinse.</article-title>
            <source>BMC Pharmacol Toxicol</source>
            <year>2013</year>
            <month>Sep</month>
            <day>03</day>
            <volume>14</volume>
            <fpage>43</fpage>
            <pub-id pub-id-type="pmid">24004959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burgess</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Brunton</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Burgess</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Single application of 4% dimeticone liquid gel versus two applications of 1% permethrin creme rinse for treatment of head louse infestation: a randomised controlled trial.</article-title>
            <source>BMC Dermatol</source>
            <year>2013</year>
            <month>Apr</month>
            <day>01</day>
            <volume>13</volume>
            <fpage>5</fpage>
            <pub-id pub-id-type="pmid">23548062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sunderk&#x000f6;tter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Feldmeier</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>F&#x000f6;lster-Holst</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Geisel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Klinke-Rehbein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nast</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Philipp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sachs</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stingl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stoevesandt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>S1 guidelines on the diagnosis and treatment of scabies - short version.</article-title>
            <source>J Dtsch Dermatol Ges</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>11</issue>
            <fpage>1155</fpage>
            <page-range>1155-1167</page-range>
            <pub-id pub-id-type="pmid">27879074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coleman</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Gillespie</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Probable topical permethrin-induced neck dystonia.</article-title>
            <source>Pharmacotherapy</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>448</fpage>
            <page-range>448-50</page-range>
            <pub-id pub-id-type="pmid">15843294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hill</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Scabies in babies.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>690</fpage>
            <page-range>690-694</page-range>
            <pub-id pub-id-type="pmid">28833468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoffmann</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>M&#x000f6;&#x000df;ner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;n</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Lippert</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Topical scabies therapy with permethrin is effective and well tolerated in infants younger than two months.</article-title>
            <source>J Dtsch Dermatol Ges</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>597</fpage>
            <page-range>597-600</page-range>
            <pub-id pub-id-type="pmid">31115965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meinking</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Taplin</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Safety of permethrin vs lindane for the treatment of scabies.</article-title>
            <source>Arch Dermatol</source>
            <year>1996</year>
            <month>Aug</month>
            <volume>132</volume>
            <issue>8</issue>
            <fpage>959</fpage>
            <page-range>959-62</page-range>
            <pub-id pub-id-type="pmid">8712847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goksugur</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Karatas</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Goksugur</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bekdas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Demircioglu</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Metabolic acidosis in an infant associated with permethrin toxicity.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2015</year>
            <season>Jan-Feb</season>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>e15</fpage>
            <page-range>e15-7</page-range>
            <pub-id pub-id-type="pmid">25487692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27033.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drago</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Acute permethrin neurotoxicity: Variable presentations, high index of suspicion.</article-title>
            <source>Toxicol Rep</source>
            <year>2014</year>
            <volume>1</volume>
            <fpage>1026</fpage>
            <page-range>1026-1028</page-range>
            <pub-id pub-id-type="pmid">28962315</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
